. 2022 May 11;12:906370. doi: 10.3389/fonc.2022.906370

Table 1.

Baseline characteristics and interventions included in the meta-analysis.

Author	Year	Country	Study design	Interventions	Sample size		Age (years)		PSA level (ng/ml)		Follow−up(months)
					NCHT+RP	RP	NCHT+RP	RP	NCHT+RP	RP	NCHT+RP	RP
Nosov et al. (17)	2016	Russia	Retrospective	Docetaxel + prednisolone + RP versus RP alone	21	23	64^a	65^a	28.5^a	31.9^a	141.6^a	128.4^a
Fujita et al. (18)	2017	Japan	Retrospective	Estramustine phosphate + GnRH agonist or antagonist versus RP alone	436	177	68^a	68^a	9.94^a	11.8^a	48.8^a	111^a
Narita et al. (19)	2019	Japan	RCT	Docetaxel + estramustine + androgen blockade + RP versus RP alone	56	56	65.4^b	66.4^b	26.7^b	23.4^b	NA	NA
Pan et al. (20)	2019	China	Retrospective	Docetaxel +androgen blockade + RP versus RP alone	60	44	65^a	69^a	93.2^a	60.3^a	12.5^a	22.8^a
Eastham et al. (21)	2020	Multicenter	RCT	Docetaxel + androgen deprivation +RP versus RP alone	391	397	62^a	63^a	9.5^a	10.2^a	73.2^a
Chi et al. (21)	2021	China	Prospective	Docetaxel + leuprorelin/goserelin +prednisone + RP versus RP alone	34	22	66.0^b	68.29^b	97.7^b	75^b	NA	NA

^aMedian, ^bMean.

PSA, prostate-specific antigen; NCHT, neoadjuvant chemohormonal therapy; RP, radical prostatectomy; RCT, randomized controlled trial.